Recent Regulatory Developments India’s biopharmaceutical industry stands at an inflection point where its scientific capabilities and production scale are increasingly recognized globa...
Key Highlights: Implications: Nubeqa’s India approval intensifies mHSPC competition against Janssen’s Erleada, amid prostate therapeutics market growing at 8.2% CAGR to $739M by 2030. ...
Key Highlights: Implications: Imfinzi storms endometrial cancer protocols, giving oncologists a potent immunotherapy combo that leapfrogs chemo-only standards. AstraZeneca doubles do...
Key Highlights: Implications: Durvalumab storms earlier gastric cancer treatment, snatching share from chemo-only protocols as oncologists embrace immunotherapy combo superiority.&nb...
Key Highlights: Implications: Sun ignites generics price war against Novo/Eli Lilly premium brands, slashing obesity therapy costs and exploding Tier-2/3 access. Dual T2D/weight...
